Navigation Links
OriGene to Acquire SDIX's Life Science Business Assets
Date:4/8/2013

ROCKVILLE, Md., April 8, 2013 /PRNewswire/ -- OriGene Technologies, Inc., a leading genome wide product company for research and diagnostic applications with operations in the United States and China, announced that it has signed a definitive agreement to acquire all the assets of the Life Science business of SDIX™ (NASDAQ: SDIX), a leading provider of biotechnology-based products and services. 

(Logo: http://photos.prnewswire.com/prnh/20130408/DC90285LOGO)

"We anticipate the combination of SDIX with OriGene will enhance our ability to continue to develop the most comprehensive collection of high-quality monoclonal antibodies for key applications both in research and diagnostics fields.  SDIX's over 20 years of antibody development and production expertise will complement OriGene's existing high-throughput monoclonal antibody capacity to develop the highest quality antibodies such as UltraMAB™," said Wei-Wu He , Ph.D., OriGene's Chairman and Chief Executive Officer.  OriGene expects the acquisition of SDIX to:

  • Enhance the capabilities of OriGene to provide the most comprehensive immunization strategies for antibody development using full-length mammalian produced protein and genetic immunization technologies to create the highest quality monoclonal antibodies available
  • Expand antibody and IVD reagent product and services capabilities to create significant new commercial opportunities for our existing and new customers including producing UltraMAB™ for future diagnostic uses

This transaction will uniquely position OriGene as one of the leaders in antibody development and production to help our customers find the best solutions for their antibody and assay needs.  The acquisition is expected to be completed during the second quarter of 2013, subject to the approval of SDIX's shareholders and other customary closing conditions.

About OriGene Technologies

OriGene Technologies, Inc. develops, manufactures, and sells genome wide research and diagnostic products worldwide.  OriGene has developed an extensive array of ultra-specific monoclonal antibodies called UltraMAB™ which offers significant improvement over traditional antibodies in antibody specificity.  UltraMAB™ antibodies are validated by OriGene's proprietary high density microarray technology for a wide variety of antibody applications. 

For more information, visit www.origene.com.


'/>"/>
SOURCE OriGene Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. The PROOF Centre of Excellence Partners with OriGene Technologies on Heart & Kidney Transplant Biomarker Program
2. OriGene Technologies Raises $21.3 Million in Series C Funding
3. Chandler Chicco Companies Acquires Haas & Health Partner Public Relations and SanCom Creative Communication Solutions, Creating Unrivalled Healthcare Communication Capability in Germany
4. S.E.D. Labs to be Acquired by Quest Diagnostics
5. Celtaxsys Acquires Clinical Stage Innate Immunity Drug for Inflammation
6. TrovaGene Acquires CLIA - Certified Laboratory
7. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
8. Elsevier Acquires QUOSA, Provider of Life Sciences Content Management and Workflow Productivity Solutions
9. LoneStar Heart Acquires Worldwide Exclusive Rights to New Class of Small Molecules That May Lead to New Treatments for Diabetes
10. inVentiv Health to Acquire SDI Promotional and Medical Audit Businesses From IMS Health
11. GeneThera, Inc. Acquires Applied Genetics, S.A.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Global demand for ... percent through 2020 to $7.2 billion.  This market ... beverages, cleaning products, biofuel production, animal feed, and ... diagnostics, and biocatalysts). Food and beverages will remain ... by increasing consumption of products containing enzymes in ...
(Date:6/27/2016)... June 27, 2016  Sequenom, Inc. (NASDAQ: ... healthier lives through the development of innovative products and ... the United States denied its petition ... claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") ... established by the Supreme Court,s Mayo Collaborative Services v. ...
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... for clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT ... care circle with the physician and clinical trial team. , Using the CONSULT module, ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
Breaking Biology Technology:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
Breaking Biology News(10 mins):